PARIS, France – 30 April 2020 – Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the filing of its 2019 Universal Registration Document (URD) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (AMF).
This 2019 Registration Document includes in particular:
- The 2019 annual financial report,
- The management report,
- The report on corporate governance.
This document can be accessed on the Investors section of the Company’s website at www.lysogene.com. In addition, the Universal Registration Document is available on the AMF’s website at www.amf- france.org.
Printed copies of both documents are available, free of charge, at the Company’s headquarters and registered office located at 18-20 rue Jacques Dulud, 92 200 Neuilly-sur-Seine, France.
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.
Stéphane Durant des Aulnois Chief Financial Officer
+ 33 1 41 43 03 99